EA038370B1 - Способы лечения рассеянного склероза - Google Patents

Способы лечения рассеянного склероза Download PDF

Info

Publication number
EA038370B1
EA038370B1 EA201791101A EA201791101A EA038370B1 EA 038370 B1 EA038370 B1 EA 038370B1 EA 201791101 A EA201791101 A EA 201791101A EA 201791101 A EA201791101 A EA 201791101A EA 038370 B1 EA038370 B1 EA 038370B1
Authority
EA
Eurasian Patent Office
Prior art keywords
patient
dmf
dimethyl fumarate
pml
patients
Prior art date
Application number
EA201791101A
Other languages
English (en)
Russian (ru)
Other versions
EA201791101A1 (ru
Inventor
Марк Новас
Жуй Чжан (Жай)
Original Assignee
Байоджен Ма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54771192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA038370(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Байоджен Ма Инк. filed Critical Байоджен Ма Инк.
Publication of EA201791101A1 publication Critical patent/EA201791101A1/ru
Publication of EA038370B1 publication Critical patent/EA038370B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/492—Determining multiple analytes
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B19/00—Teaching not covered by other main groups of this subclass
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Business, Economics & Management (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Ecology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Educational Administration (AREA)
  • Theoretical Computer Science (AREA)
  • Educational Technology (AREA)
EA201791101A 2014-11-17 2015-11-16 Способы лечения рассеянного склероза EA038370B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462080783P 2014-11-17 2014-11-17
US201562140255P 2015-03-30 2015-03-30
US201562232963P 2015-09-25 2015-09-25
PCT/US2015/060850 WO2016081355A1 (en) 2014-11-17 2015-11-16 Methods of treating multiple sclerosis

Publications (2)

Publication Number Publication Date
EA201791101A1 EA201791101A1 (ru) 2017-12-29
EA038370B1 true EA038370B1 (ru) 2021-08-17

Family

ID=54771192

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791101A EA038370B1 (ru) 2014-11-17 2015-11-16 Способы лечения рассеянного склероза

Country Status (13)

Country Link
US (8) US20170354630A1 (enExample)
EP (3) EP3804711A1 (enExample)
JP (5) JP6786486B2 (enExample)
KR (3) KR102299842B1 (enExample)
CN (6) CN115501218A (enExample)
AU (4) AU2015350213A1 (enExample)
CA (1) CA2967619C (enExample)
EA (1) EA038370B1 (enExample)
IL (2) IL269885B (enExample)
MA (2) MA40985A (enExample)
MX (1) MX2017006473A (enExample)
WO (1) WO2016081355A1 (enExample)
ZA (1) ZA201703207B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3116536A1 (en) 2014-03-14 2017-01-18 Biogen MA Inc. Dimethyl fumarate and vaccination regimens
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
SI3253377T1 (sl) 2015-02-08 2021-08-31 Alkermes Pharma Ireland Limited Monometilfumaratni sestavki predzdravil
US10868332B2 (en) 2016-04-01 2020-12-15 NOHMs Technologies, Inc. Modified ionic liquids containing phosphorus
EP4087005A1 (en) 2017-07-17 2022-11-09 Nohms Technologies, Inc. Phosphorus-containing electrolytes
EP4578850A3 (en) * 2019-04-17 2025-10-15 Myto Therapeutics, Inc. Prodrugs of monomethyl fumarate
PH12021552668A1 (en) * 2019-05-31 2022-09-19 Curacle Co Ltd Enteric tablet containing dimethyl fumarate
TW202116297A (zh) * 2019-07-03 2021-05-01 西班牙商布爾奴爾法碼有限公司 組合療法之方法、組成物與套組
CN111440771A (zh) * 2020-03-17 2020-07-24 中山大学附属第三医院 一种含有clcn2纯合突变的白质脑病患者特异诱导多能干细胞系
EP4146190A2 (en) 2020-05-06 2023-03-15 Imcyse SA Combination treatment for fumarate-related diseases
KR102713565B1 (ko) * 2020-11-27 2024-10-07 주식회사 뷰노 의료 영상 기반의 뇌백질 병변 탐지 방법
WO2022203432A1 (ko) * 2021-03-25 2022-09-29 주식회사 큐라클 특정 약동학적 매개변수를 나타내는 디메틸푸마레이트를 유효성분으로 함유한 약학적 조성물
KR102566549B1 (ko) * 2021-06-08 2023-08-14 제이투에이치바이오텍 (주) 3성분 프로드럭, 이의 약학적 조성물 및 의약 용도
US20250181224A1 (en) * 2023-12-01 2025-06-05 Lemon Inc. Implementing dialog-based image editing

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207141A1 (en) * 2006-02-28 2007-09-06 Ivan Lieberburg Methods of treating inflammatory and autoimmune diseases with natalizumab

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE19721099C2 (de) 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
PL2316430T3 (pl) 2004-10-08 2012-11-30 Forward Pharma As Kompozycje farmaceutyczne o kontrolowanym uwalnianiu, zawierające ester kwasu fumarowego
EP3135282A1 (en) * 2007-02-08 2017-03-01 Biogen MA Inc. Neuroprotection in demyelinating diseases
HRP20140640T1 (hr) 2008-08-19 2014-11-21 Xenoport, Inc. Prolijekovi monometil estera fumarne kiseline, farmaceutski sastavi iz toga i postupci njihove uporabe
DK4152004T3 (da) 2010-01-11 2025-02-24 Biogen Ma Inc Analyse for jc-virusantistoffer
KR20140036257A (ko) 2011-05-26 2014-03-25 바이오겐 아이덱 엠에이 인코포레이티드 다발성 경화증 치료 및 미엘린 함량 보존 및/또는 증가 방법
DK2715352T3 (da) 2011-05-31 2019-05-20 Biogen Ma Inc Fremgangsmåde til vurdering af risiko for pml
JP6189333B2 (ja) 2012-02-07 2017-08-30 バイオジェン エムエー インコーポレーテッド フマル酸ジメチルを含有する医薬組成物
US20140057918A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of Use for Monomethyl Fumarate and Prodrugs Thereof
WO2014071371A1 (en) 2012-11-05 2014-05-08 Xenoport, Inc. Cocrystals of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate
JP6506174B2 (ja) 2012-12-21 2019-04-24 バイオジェン エムエー インコーポレイテッド 重水素置換されたフマル酸誘導体
ES2731837T3 (es) 2012-12-21 2019-11-19 Ratiopharm Gmbh Profármacos de fumarato de monometilo (MMF)
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US20140322252A1 (en) 2013-04-26 2014-10-30 Michael Ruff Peptides for Treating Alzheimers's Disease and Related Conditions
WO2015017762A1 (en) 2013-08-01 2015-02-05 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
ES2713157T3 (es) 2014-02-28 2019-05-20 Banner Life Sciences Llc Cápsulas blandas entéricas de liberación controlada de ésteres de fumarato
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
EP3116536A1 (en) 2014-03-14 2017-01-18 Biogen MA Inc. Dimethyl fumarate and vaccination regimens
CA2962916C (en) 2014-10-08 2021-06-15 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
MA40985A (fr) * 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
WO2017040272A1 (en) 2015-08-31 2017-03-09 Banner Life Sciences Llc Fumarate ester dosage forms
WO2017151184A1 (en) 2016-02-29 2017-09-08 Banner Life Sciences Llc Fumarate ester dosage forms
US10523918B2 (en) 2017-03-24 2019-12-31 Samsung Electronics Co., Ltd. System and method for depth map

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207141A1 (en) * 2006-02-28 2007-09-06 Ivan Lieberburg Methods of treating inflammatory and autoimmune diseases with natalizumab

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"DIMETHYL FUMARATE (TECFIDERA) AND PML RESULTING IN DEATH", 7 November 2014 (2014-11-07), pages 1-1, XP055247812, Retrieved from the Internet: URL:http://www.pbm.va.gov/PBM/vacenterformedicationsafety/nationalpbmbulletin/Dimethyl_Fumarate_Tecfidera_and_PML_Resulting_in Death_NATIONAL_PBM_Bulletin.pdf [retrieved on 2016-02-05], abstract *
"SUMMARY OF PRODUCT CHARACTERISTICS TECFIDERA", 11 October 2014 (2014-10-11), pages 1-49, XP055247806, Retrieved from the Internet: URL:https://web.archive.org/web/20141011193051/http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002601/ WC500162069.pdf [retrieved on 2016-02-05], sections "Blood/laboratory tests" and "Haematological" on page 3, 7, 17 and 21 *

Also Published As

Publication number Publication date
CA2967619C (en) 2022-06-28
AU2020239734A1 (en) 2020-10-15
CN113368092A (zh) 2021-09-10
EP3804711A1 (en) 2021-04-14
CN113368091A (zh) 2021-09-10
NZ731528A (en) 2021-11-26
KR102299842B1 (ko) 2021-09-09
US20210315854A1 (en) 2021-10-14
JP2022168243A (ja) 2022-11-04
JP6830941B2 (ja) 2021-02-17
JP2025109834A (ja) 2025-07-25
CN115501218A (zh) 2022-12-23
US20190125710A1 (en) 2019-05-02
US11129806B2 (en) 2021-09-28
JP6786486B2 (ja) 2020-11-18
WO2016081355A1 (en) 2016-05-26
KR20170084270A (ko) 2017-07-19
US10959972B2 (en) 2021-03-30
CN113368093A (zh) 2021-09-10
EP4215191A1 (en) 2023-07-26
AU2024203437A1 (en) 2024-06-13
IL252296B (en) 2022-06-01
JP2017537089A (ja) 2017-12-14
AU2015350213A1 (en) 2017-05-25
IL269885B (en) 2022-06-01
US20210023040A1 (en) 2021-01-28
US11246850B2 (en) 2022-02-15
US20200345679A1 (en) 2020-11-05
US11007166B2 (en) 2021-05-18
US20180000770A1 (en) 2018-01-04
US20190008817A1 (en) 2019-01-10
EP3220907A1 (en) 2017-09-27
MA40985A (fr) 2017-09-26
US20170354630A1 (en) 2017-12-14
ZA201703207B (en) 2021-08-25
KR20210111362A (ko) 2021-09-10
MX2017006473A (es) 2018-01-30
EA201791101A1 (ru) 2017-12-29
CN115531366A (zh) 2022-12-30
KR20240035912A (ko) 2024-03-18
CA2967619A1 (en) 2016-05-26
CN107106530A (zh) 2017-08-29
MA53882A (fr) 2021-12-08
US11007167B2 (en) 2021-05-18
IL252296A0 (en) 2017-07-31
AU2021269298A1 (en) 2021-12-09
JP2020196760A (ja) 2020-12-10
US20170368013A1 (en) 2017-12-28
JP2019023248A (ja) 2019-02-14

Similar Documents

Publication Publication Date Title
EA038370B1 (ru) Способы лечения рассеянного склероза
AU2015212613A1 (en) Use of cladribine for treating neuromyelitis optica
WO2016090154A1 (en) Multiple sclerosis treatment regimen using dimethyl fumarate
HK40097430A (en) Composition comprising a fumarate for use in a method of treating multiple sclerosis
AU2011237834A1 (en) Plasma-derived immunoglobulin for use in the treatment and prevention of immune reconstitution inflammatory syndrome (IRIS)
HK40047494A (en) Methods of treating multiple sclerosis
NZ731528B2 (en) Methods of treating multiple sclerosis